What is AXSM's market cap?

$7.18B, based on the Nov 4 close of $137.00.

Does Axsome Therapeutics pay a dividend?

No regular cash dividend has been paid in the last year.

How much of AXSM is sold short?

3.1M shares, 7.6% of float, as of Oct 15, 2026.

What sector is AXSM in?

Healthcare, in the Pharmaceuticals industry.

NASDAQ · AXSMHealthcarePharmaceuticals

Axsome Therapeutics, Inc (AXSM)

$137.00−1.87%

Close Nov 4, 2026 · split-adjusted

Nov 3, 2026$139.61▲ 2.84% in range

Nov 3, 2025Low $134.93 · High $255.17Nov 3, 2026

What changed · written from our data

As of Nov 4, 2026

Axsome Therapeutics closed at $137.00 on Nov 4, down 1.87%, within 1.5% of its 52-week closing low. Volume of 1.0M shares was 0.94× its 20-day average (close to normal).

Split-adjusted performance: -21.4% over one month, -38.5% over six months, +0.9% over one year.

In the quarter ended Sep 30, 2026, revenue was $259.69M, up 51.9% from a year earlier, with a net margin of -5.0%.

Short interest was 3.1M shares at the Oct 15 settlement, down 5.9% from the prior report (7.6% of float, 3.3 days to cover).

Market cap$7.18B52.4M shares

Revenue · quarter$259.7M+51.9% YoY

Diluted EPS$-0.25—

P/E · TTM—P/S 8.3×

Net margin-5.0%Gross 93.1%

Dividend yieldNone

52-week range134.93 – 255.17−46.3% from high

Volume1.0M0.94× 20-day avg

Volatility · 60d38.0%Annualised

Short % of float7.6%3.3 days to cover

Net cash$116.6MCash $313.9M

Next earnings—Not scheduled

Split-adjusted performance

1W −4.5%1M −21.4%3M −34.8%6M −38.5%YTD −25.0%1Y +0.9%3Y +128.2%5Y +249.1%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum35

Revenue growth79

Net margin66

Value (low P/E)—

Size92

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →

Shares short3.1M−5.9% vs prior

Days to cover3.3Settled Oct 15

% of float7.6%

Short vol. 10d56.7%of daily volume

Closest peers by size in Pharmaceuticals

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
AXSMAxsome Therapeutics	$137.00	−1.87%	−38.5%	+51.9%	−5.0%	—	$7.18B
AMRXAmneal Pharmaceuticals	$19.95	−1.29%	+46.5%	+9.9%	7.2%	44.2	$6.95B	Compare
KNSAKiniksa Pharmaceuticals International	$96.12	+3.03%	+65.1%	+58.1%	16.6%	68.9	$7.55B	Compare
RYTMRhythm Pharmaceuticals	$110.68	+28.04%	+14.6%	+46.9%	−70.7%	—	$7.62B	Compare
ORKAOruka Therapeutics	$101.41	+1.87%	+45.3%	—	—	—	$6.71B	Compare
ALKSAlkermes	$45.89	+0.44%	+29.9%	+21.8%	3.4%	—	$7.70B	Compare
IONSIonis Pharmaceuticals	$40.15	−0.67%	−47.8%	−40.7%	−42.8%	—	$6.67B	Compare
PRAXPraxis Precision Medicines	$284.79	+1.53%	−15.8%	—	—	—	$7.95B	Compare
LGNDLigand Pharmaceuticals	$316.13	+0.83%	+35.9%	−31.8%	−36.2%	122.9	$6.32B	Compare

News about Axsome Therapeutics

All news →

Axsome Therapeutics (AXSM) Reports Q3 Loss, Tops Revenue EstimatesZacks Investment Research · 2d agoNeutral Axsome Therapeutics vs. Moderna: Consistent Revenue Growth or Sharp VolatilityThe Motley Fool · Oct 28, 2026▲ Positive Will Axsome Therapeutics (AXSM) Report Negative Earnings Next Week? What You Should KnowZacks Investment Research · Oct 26, 2026▼ Negative Will Auvelity Continue to Aid Axsome's Top-Line Growth in Q3?Zacks Investment Research · Oct 21, 2026▲ Positive Where Will Axsome Therapeutics Be in 2030 as Auvelity Expands Into Alzheimer's?The Motley Fool · Oct 12, 2026▲ Positive

Quick answers

What does Axsome Therapeutics do?: Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options.
What is AXSM's market cap?: $7.18B, based on the Nov 4 close of $137.00.
Does Axsome Therapeutics pay a dividend?: No regular cash dividend has been paid in the last year.
How much of AXSM is sold short?: 3.1M shares, 7.6% of float, as of Oct 15, 2026.
What sector is AXSM in?: Healthcare, in the Pharmaceuticals industry.

About Axsome Therapeutics

Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.

HQ: New York, NY925 employeesListed Nov 19, 2015axsome.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology